Source: jpml.uscourts.gov
The Wire · Case news
What changed. Why it matters.
Court rulings, settlements, and case developments, with links to the source records.
Roblox child abuse
JPML transfer order (MDL No. 3166, Doc. 98) created In re: Roblox Corporation Child Sexual Exploitation and Assault Litigation, centralizing 31 actions from 12 districts (with 48 noticed tag-alongs, ~80 total actions) in the Northern District of California before Chief Judge Richard Seeborg, over opposition from defendants Roblox, Discord, Snap, and Meta; the order notes Louisiana, Kentucky, and Texas AG suits and a Florida AG criminal investigation. Suboxone lawsuit: who can file and what happens next
JPML transfer order (MDL No. 3092, Doc. 50) centralized 15 Suboxone film tooth-decay actions from five districts in the Northern District of Ohio before Judge J. Philip Calabrese, renaming the litigation 'In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation'; 11 additional related actions already noticed as potential tag-alongs. Source: jpml.uscourts.gov
Zantac claim: what to ask and what to do
MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) omnibus Daubert order (Doc 6120, 341 pages): ALL defendants' Daubert motions on general causation GRANTED and defendants' summary judgment motion GRANTED — plaintiffs 'fail to produce admissible primary evidence of general causation' that ranitidine causes cancer, ending the federal MDL claims. MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) omnibus Daubert order (Doc 6120, 341 pages): ALL defendants' Daubert motions on general causation GRANTED and defendants' summary judgment motion GRANTED — plaintiffs 'fail to produce admissible primary evidence of general causation' that ranitidine causes cancer, ending the federal MDL claims. Verified from the court order itself.
Source: gsk.com
Zantac claim: what to ask and what to do
Sanofi agreed to pay more than $100 million to settle ~4,000 Zantac cancer suits in state courts outside Delaware — the first major resolution in the litigation, averaging more than $25,000 per claim per Bloomberg's reporting (republished by Insurance Journal, Apr 23, 2024; deal announced earlier that month). Sanofi agreed to pay more than $100 million to settle ~4,000 Zantac cancer suits in state courts outside Delaware — the first major resolution in the litigation, averaging more than $25,000 per claim per Bloomberg's reporting (republished by Insurance Journal, Apr 23, 2024; deal announced earlier that month). Sanofi denied liability; 70,000+ suits then remained, mostly in Delaware.
Source: insurancejournal.com
Zantac claim: what to ask and what to do
GSK announced agreements with 10 plaintiff firms representing ~80,000 claimants (93% of pending US state-court Zantac cases) to pay up to $2.2 billion in aggregate, with full implementation expected by end of H1 2025; GSK admitted no liability. GSK announced agreements with 10 plaintiff firms representing ~80,000 claimants (93% of pending US state-court Zantac cases) to pay up to $2.2 billion in aggregate, with full implementation expected by end of H1 2025; GSK admitted no liability. GSK also agreed to pay $70 million to resolve the Valisure qui tam complaint. Verified from GSK's own press statement.
Source: us.gsk.com
Depo-Provera shots and brain tumor claims
Settlement in principle announced; docket had grown +1,739 filings (+46%) in the single preceding month — the leading-indicator pattern. Source: jpml.uscourts.gov
Talc body powder claims: what to check
Ingham v. Johnson & Johnson: $4.69B verdict to 22 plaintiffs, later reduced to $2.1B on appeal — headline verdicts routinely shrink. Source: biospace.com
Coal ash, exposure and possible claims
EPA Issues Major Penalties in Chemical Facility Enforcement Actions EPA enforcement records detected in July 2026 show federal penalties issued against multiple chemical facilities. Denka Performance Elastomer was assessed a penalty of $996,703 under EPA case 06-2025-0910. Separate actions recorded penalties of $1,265,246 against Hasa, Inc. and $541,110 against AMVAC. The applicable laws, filing dates, and facility locations were not specified in the available enforcement data.
Source: echo.epa.gov
Ozempic and GLP-1 gut injury claims
FDA Issues Class I Recall for Omnipod 5 Insulin Pods Over Leak Risk The FDA posted a Class I recall for specific Omnipod 5 pod models manufactured by Insulet Corporation. According to the recall notice, a manufacturing defect can damage the external soft cannula, causing insulin to leak around the pod rather than being delivered to the user. The FDA noted that failure to deliver insulin properly could lead to serious health consequences.
Source: api.fda.gov
Coal ash, exposure and possible claims
EPA Issues ~$997K Penalty Against Denka Performance Elastomer EPA enforcement case 06-2025-0910 lists a federal penalty of $996,703 against Denka Performance Elastomer, according to EPA's ECHO database. The record was detected on July 15, 2026. No further case details — including the specific law cited, filing date, or facility location — were available in the signal.
Source: echo.epa.gov
Truck crash claim: what can I do?
NHTSA Opens Multiple Truck-Related Safety Investigations in 2026 Between March and July 2026, NHTSA opened at least five separate investigations into potential truck safety defects. The probes cover issues including front steering knuckle fractures, rear toe link separation, wheel fastener locking mechanisms, carry handle separation, and fuel smell paired with loss of power. No vehicle makes, models, or docket numbers were included in the available signal data.
Source: nhtsa.gov
PFAS in Water: What to Check
Study Finds PFAS in Kidney Tissue Linked to Doubled Transplant Risk; EPA Issues $1.2M Fine A peer-reviewed study published July 9, 2026 in Environmental Pollution (PMID 42425288) found PFAS chemicals in renal vascular tissue from brain-dead organ donors and reported a risk ratio of 2.0 for post-transplant delayed graft function. Separately, the EPA recorded an enforcement action against Hasa, Inc. (Case No. 09-2026-3564) carrying a federal penalty of $1,265,246.
Source: pubmed.ncbi.nlm.nih.gov